Analysts take a look at Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) having this to say.

April 17, 2018 - By reb123z

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) LogoInvestors sentiment decreased to 1.03 in Q4 2017. Its down 0.14, from 1.17 in 2017Q3. It dropped, as 65 investors sold Alexion Pharmaceuticals, Inc. shares while 171 reduced holdings. 64 funds opened positions while 178 raised stakes. 204.38 million shares or 1.21% less from 206.89 million shares in 2017Q3 were reported.
Bridgewater Assoc Limited Partnership holds 0.06% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 65,212 shares. Great West Life Assurance Can has invested 0.05% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Zurcher Kantonalbank (Zurich Cantonalbank) invested 0.08% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Moreover, Blackrock has 0.1% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 18.00M shares. Federated Pa owns 194,014 shares. Mackenzie Corporation reported 3,150 shares. Bnp Paribas Arbitrage owns 150,803 shares. Connecticut-based Mark Sheptoff Financial Planning Ltd Llc has invested 0.01% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Amalgamated Bankshares owns 28,599 shares for 0.09% of their portfolio. Arrowstreet Capital Limited Partnership holds 310,900 shares or 0.09% of its portfolio. 7,628 are held by First Quadrant Lp Ca. Meeder Asset Mgmt has invested 0.05% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Private Advisor Limited Liability Corp has 0.02% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Credit Suisse Ag invested in 368,469 shares. 15 are owned by Delta Asset Ltd Liability Co Tn.

Since January 2, 2018, it had 0 insider purchases, and 12 insider sales for $4.62 million activity. 1,261 shares valued at $147,865 were sold by Moriarty John B on Monday, February 5. Wagner Heidi L sold 655 shares worth $76,805. 2,553 shares valued at $310,521 were sold by HANTSON LUDWIG on Tuesday, January 2. Shares for $169,696 were sold by Franchini Indrani Lall on Tuesday, February 6. $192,028 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) was sold by Goff Brian on Tuesday, February 6. $707,048 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) was sold by Clancy Paul J on Tuesday, February 6.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Ratings Coverage

Among 14 analysts covering Alexion Pharmaceuticals (NASDAQ:ALXN), 13 have Buy rating, 0 Sell and 1 Hold. Therefore 93% are positive. Alexion Pharmaceuticals had 26 analyst reports since October 20, 2017 according to SRatingsIntel. Deutsche Bank maintained Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Thursday, March 15 with “Buy” rating. The firm earned “Buy” rating on Thursday, February 8 by Stifel Nicolaus. SunTrust maintained Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) rating on Monday, February 12. SunTrust has “Buy” rating and $172.0 target. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has “Buy” rating given on Friday, February 9 by Deutsche Bank. The company was maintained on Tuesday, October 24 by Robert W. Baird. The rating was maintained by Citigroup with “Buy” on Friday, February 9. SunTrust maintained the stock with “Buy” rating in Monday, October 23 report. The firm has “Outperform” rating given on Friday, February 9 by Leerink Swann. Leerink Swann maintained it with “Buy” rating and $169.0 target in Wednesday, December 6 report. As per Thursday, February 8, the company rating was maintained by Jefferies. Below is a list of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) latest ratings and price target changes.

19/03/2018 Broker: Nomura Old Rating: Buy New Rating: Buy Old Target: $148 New Target: $156 Maintain
16/03/2018 Broker: Credit Suisse Old Rating: Outperform New Rating: Outperform Old Target: $147 New Target: $149 Maintain
15/03/2018 Broker: Robert W. Baird Rating: Buy New Target: $160.0 Maintain
15/03/2018 Broker: Deutsche Bank Rating: Buy New Target: $161.0 Maintain
12/02/2018 Broker: SunTrust Rating: Buy New Target: $172.0 Maintain
08/02/2018 Broker: Stifel Nicolaus Rating: Buy New Target: $151.0 Maintain
09/02/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $148 New Target: $151 Maintain
09/02/2018 Broker: Leerink Swann Old Rating: Outperform New Rating: Outperform Old Target: $166 New Target: $153 Maintain
09/02/2018 Broker: Deutsche Bank Old Rating: Buy New Rating: Buy Old Target: $163 New Target: $161 Maintain
09/02/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $173 New Target: $170 Maintain

The stock increased 3.47% or $3.8 during the last trading session, reaching $113.28. About 1.63M shares traded. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 8.84% since April 17, 2017 and is downtrending. It has underperformed by 20.39% the S&P500.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company has market cap of $25.19 billion. The firm offers Soliris , a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It has a 57.5 P/E ratio. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.